Last reviewed · How we verify
Daphnetin
At a glance
| Generic name | Daphnetin |
|---|---|
| Also known as | gradient compression stocking, 7,8-dihydroxycoumarin |
| Sponsor | The First Hospital of Jilin University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) (NA)
- Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia (NA)
- Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daphnetin CI brief — competitive landscape report
- Daphnetin updates RSS · CI watch RSS
- The First Hospital of Jilin University portfolio CI